Abstract
Nanoparticles can be effective drug delivery systems for treating bacterial and fungal infections in the skin. The nanoparticles used for drug therapy give many advantages over conventional formulations, such as increased solubility and storage stability, improved permeability and bioavailability, prolonged half-life, tissue targeting, and minimal side effects. In recent years, the concept of using nanoparticles to treat skin-microbiomerelated diseases has attracted increasing attention. This review article aimed to introduce recent progress using nanomedical strategies for drug delivery. Various modalities of nanocarriers can be used for antimicrobial therapy of disease, including liposomes, microemulsions, solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), and polymeric nanoparticles. This review systematically describes the structures and physicochemical properties of different nanocarriers, emphasizing antibacterial activity of nanoparticles for inhibiting infection. Nanoparticles for treating appendageal bacteria have gained attention in recent years, in particular, nanomedical approaches for managing acne. Issues related to the treatment of non-appendageal bacteria and fungi are also discussed. Finally, current obstacles to using nanocarriers for delivering medicines aimed at inhibiting infection and future developments are addressed.
Keywords: Antibacterial activity, drug delivery, microbiome, nanomedicine, skin.
Current Drug Metabolism
Title:Nanomedical Strategies for Targeting Skin Microbiomes
Volume: 16 Issue: 4
Author(s): Ibrahim A. Aljuffali, Chun-Hsun Huang and Jia-You Fang
Affiliation:
Keywords: Antibacterial activity, drug delivery, microbiome, nanomedicine, skin.
Abstract: Nanoparticles can be effective drug delivery systems for treating bacterial and fungal infections in the skin. The nanoparticles used for drug therapy give many advantages over conventional formulations, such as increased solubility and storage stability, improved permeability and bioavailability, prolonged half-life, tissue targeting, and minimal side effects. In recent years, the concept of using nanoparticles to treat skin-microbiomerelated diseases has attracted increasing attention. This review article aimed to introduce recent progress using nanomedical strategies for drug delivery. Various modalities of nanocarriers can be used for antimicrobial therapy of disease, including liposomes, microemulsions, solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), and polymeric nanoparticles. This review systematically describes the structures and physicochemical properties of different nanocarriers, emphasizing antibacterial activity of nanoparticles for inhibiting infection. Nanoparticles for treating appendageal bacteria have gained attention in recent years, in particular, nanomedical approaches for managing acne. Issues related to the treatment of non-appendageal bacteria and fungi are also discussed. Finally, current obstacles to using nanocarriers for delivering medicines aimed at inhibiting infection and future developments are addressed.
Export Options
About this article
Cite this article as:
Aljuffali A. Ibrahim, Huang Chun-Hsun and Fang Jia-You, Nanomedical Strategies for Targeting Skin Microbiomes, Current Drug Metabolism 2015; 16 (4) . https://dx.doi.org/10.2174/1389200216666150812124923
DOI https://dx.doi.org/10.2174/1389200216666150812124923 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Oral Factor Xa (FXa) Inhibitors for Treatment of Heparin-induced Thrombocytopenia (HIT)
Current Drug Therapy Acute Tonsillitis
Infectious Disorders - Drug Targets Dissecting the Therapeutic Potency of Antimicrobial Peptides Against Microbial Biofilms
Current Protein & Peptide Science Valve Endothelial Cells – Not Just Any Old Endothelial Cells
Current Vascular Pharmacology Long-term Outcomes of Mitral Valve Repair Versus Replacement for Degenerative Disease: A Systematic Review
Current Cardiology Reviews Pharmacological Treatments for Obesity
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Can Statins Prevent Progression of Degenerated Aortic Valve Stenosis?
Vascular Disease Prevention (Discontinued) Effect of Treatment with Caspofungin on the Diagnosis of Fungal Infections by Gamma Scintigraphy
Current Radiopharmaceuticals Therapeutic Potential of γ -Secretase Inhibitors and Modulators
Current Topics in Medicinal Chemistry Bacterial Zinc Proteases and their Inhibition
Current Enzyme Inhibition Heart Disease in Patients with HIV/AIDS-An Emerging Clinical Problem
Current Cardiology Reviews Immunopathological Aspects of Mycoplasma pneumoniae Infection
Current Pediatric Reviews Antifungal Therapy of Aspergillosis of the Central Nervous System and Aspergillus Endophthalmitis
Current Pharmaceutical Design Thrombotic Microangiopathy and Occult Neoplasia
Cardiovascular & Hematological Disorders-Drug Targets Adherence to Secondary Prophylaxis for Acute Rheumatic Fever and Rheumatic Heart Disease: A Systematic Review
Current Cardiology Reviews Coarctation of the Aorta - The Current State of Surgical and Transcatheter Therapies
Current Cardiology Reviews Small Molecule Approaches Toward the Non-Microbicidal Modulation of Bacterial Biofilm Growth and Maintenance
Anti-Infective Agents in Medicinal Chemistry Research Progress in Live Attenuated Brucella Vaccine Development
Current Pharmaceutical Biotechnology Hybrid Drugs as Potential Combatants Against Drug-Resistant Microbes: A Review
Current Topics in Medicinal Chemistry Gene Cloning and Homology Modeling of the 3-Oxoacyl-ACP Synthase from Aeromonas hydrophila for Drug Discovery
Letters in Drug Design & Discovery